chlorpromazine has been researched along with mercaptopurine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Aquino, TM; Araújo-Júnior, JX; da Silva-Júnior, EF; Leoncini, GO; Rodrigues, ÉES | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Brodinova, NS; Moroz, AF | 1 |
| Brodinova, NS; Moroz, AF; Podboronov, VM | 1 |
| Mukhtar, H; Murti, CR | 1 |
| Chinea, G; Colombo, C; Graeme, ML; Piliero, SJ; Sigg, EB | 1 |
| BUTLER, WT; COONS, AH | 1 |
2 review(s) available for chlorpromazine and mercaptopurine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The medicinal chemistry of Chikungunya virus.
Topics: Animals; Antiviral Agents; Biological Products; Chemistry, Pharmaceutical; Chikungunya Fever; Chikungunya virus; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2017 |
17 other study(ies) available for chlorpromazine and mercaptopurine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[The increase of resistance of Staphylococcus and Escherichia coli to some antibiotics and their combinations with DNA-tropic substances].
Topics: Acridines; Ampicillin; Anti-Bacterial Agents; Antimetabolites; Azaguanine; Chlorpromazine; Escherichia coli; Flavonoids; Mercaptopurine; Neomycin; Novobiocin; Penicillin Resistance; Penicillins; Phenothiazines; Protamines; Quinacrine; Ristocetin; Staphylococcus; Streptomycin; Vasodilator Agents | 1970 |
[Prevention of the development of drug resistant forms of staphylococci by a combination of antibiotics with DNA-tropic compounds].
Topics: Acridines; Anti-Bacterial Agents; Azaguanine; Chlorpromazine; Culture Media; Depression, Chemical; DNA, Bacterial; Flavonoids; Mercaptopurine; Mutation; Novobiocin; Penicillin Resistance; Penicillins; Phenothiazines; Quinacrine; Staphylococcus; Time Factors; Vasodilator Agents | 1971 |
Induction of rat liver tyrosine aminotransferase by pharmacologically unrelated drugs.
Topics: Animals; Azaguanine; Chloroquine; Chlorpromazine; Enzyme Induction; Liver; Mercaptopurine; Phenacetin; Rats; Tetracycline; Tyrosine Transaminase | 1971 |
Action of anti-inflammatory agents upon blood and histopathologic changes induced by periarthritis in rats.
Topics: Adrenal Glands; Animals; Blood Cell Count; Blood Protein Electrophoresis; Blood Sedimentation; Chlorpromazine; Fibrinogen; Indomethacin; Male; Mercaptopurine; Methotrexate; Organ Size; Oxyphenbutazone; Paramethasone; Phenylbutazone; Rats; Spleen; Streptomycin; Thymus Gland | 1966 |
STUDIES ON ANTIBODY PRODUCTION. XII. INHIBITION OF PRIMING BY DRUGS.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Antiprotozoal Agents; Azaguanine; Chloramphenicol; Chlorpromazine; Colchicine; Dactinomycin; Edetic Acid; Hydrocortisone; Immunization; Mercaptopurine; Methotrexate; Mice; Pharmacology; Quinolines; Research; Thiotepa; Vaccination | 1964 |